Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02470234 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
A Phase 4 study, sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02470234 is a Phase 4 study that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 10 participants.
The verdict
NCT02470234, a Phase 4 study, has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.
Interventions
- DRUG Methylphenidate HCl ER Capsules, 10 mg
- DRUG Methylphenidate HCl ER Capsules, 15 mg
- DRUG Methylphenidate HCl ER Capsules, 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-07-30 |
| Est. Completion | 2017-08-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02470234
The ClinicalTrials.gov registry entry for NCT02470234 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhodes Pharmaceuticals, L.P., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Methylphenidate HCl ER Capsules, 10 mg is the first listed.
NCT02470234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02470234 about?
NCT02470234 is a clinical study titled "Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD". To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.
What is the current status of trial NCT02470234?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2016-07-30. Estimated completion is 2017-08-07.
What interventions are being tested in trial NCT02470234?
The interventions under investigation include: Methylphenidate HCl ER Capsules, 10 mg (DRUG), Methylphenidate HCl ER Capsules, 15 mg (DRUG), Methylphenidate HCl ER Capsules, 20 mg (DRUG).
Who is sponsoring clinical trial NCT02470234?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.